Improving Drug Delivery with Chemical Masks for Thiazolo-Pyrimidine Compounds

A patent describing modified chemical structures that act as dormant precursors, designed to be activated by the body to help treat viral infections like Hepatitis C.

What it covers

The patent claims a specific class of chemical compounds known as prodrugs. These are essentially inactive versions of a drug that are chemically masked with carbonate or carbamate groups. Once a patient ingests the compound, the body's natural metabolic processes strip away these masks, releasing the active medicine exactly where and when it is needed. This chemical modification is intended to improve how well the drug is absorbed or how stable it remains in the bloodstream before reaching its target.

What it doesn't cover

• —Does not cover the original, unprotected parent drug molecule itself.
• —Does not cover general chemical synthesis methods for creating thiazolo-pyrimidines.
• —Does not cover treatments for diseases other than those specifically mentioned, such as cancer or Hepatitis C.

The clever bit

The innovation lies in attaching specific carbonate or carbamate groups to the molecule to create a 'prodrug' that remains stable during storage and transit but is easily cleaved by enzymes in the body to release the active medicine.

Why it matters

Developing effective drugs is often hampered by poor solubility or rapid degradation in the body. By creating a prodrug, researchers can effectively 'hide' the active drug until it reaches the right environment, potentially increasing its potency and reducing side effects. This approach is a standard strategy in medicinal chemistry to turn promising laboratory compounds into viable clinical treatments.

Real-world examples

• 1.Experimental antiviral treatments for Hepatitis C
• 2.Potential oncology therapeutics targeting abnormal cell growth